Title |
Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients
|
---|---|
Published in |
International Journal of Chronic Obstructive Pulmonary Disease, December 2015
|
DOI | 10.2147/copd.s94797 |
Pubmed ID | |
Authors |
Hye Yun Park, Hyun Lee, Won-Jung Koh, Seonwoo Kim, Ina Jeong, Hyeon-Kyoung Koo, Tae-Hyung Kim, Jin Woo Kim, Woo Jin Kim, Yeon-Mok Oh, Don D Sin, Seong Yong Lim, Sang-Do Lee |
Abstract |
COPD patients with increased airway eosinophilic inflammation show a favorable response to inhaled corticosteroids (ICS) in combination with a long-acting bronchodilator. Recent studies have demonstrated a significant correlation of sputum eosinophilia with blood eosinophils and periostin. We investigated whether high blood eosinophils and plasma periostin were associated with an improvement in forced expiratory volume in 1 second (FEV1) after 3-month treatment with ICS/long-acting beta2-agonist (LABA) in stable COPD patients. Blood eosinophils and plasma periostin levels were measured in 130 stable COPD subjects selected from the Korean Obstructive Lung Disease cohort. Subjects began a 3-month ICS/LABA treatment after washout period. High blood eosinophils (>260/µL, adjusted odds ratio =3.52, P=0.009) and high plasma periostin (>23 ng/mL, adjusted odds ratio =3.52, P=0.013) were significantly associated with FEV1 responders (>12% and 200 mL increase in FEV1 from baseline after treatment). Moreover, the addition of high blood eosinophils to age, baseline positive bronchodilator response, and FEV1 <50% of the predicted value significantly increased the area under the curve for prediction of FEV1 responders (from 0.700 to 0.771; P=0.045). High blood eosinophils and high plasma periostin were associated with improved lung function after 3-month ICS/LABA treatment. In particular, high blood eosinophils, in combination with age and baseline lung function parameters, might be a possible biomarker for identification of COPD patients with favorable FEV1 improvement in response to ICS/LABA treatment. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 42 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 8 | 19% |
Other | 7 | 17% |
Student > Doctoral Student | 4 | 10% |
Professor | 4 | 10% |
Researcher | 3 | 7% |
Other | 7 | 17% |
Unknown | 9 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 25 | 60% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 10% |
Nursing and Health Professions | 2 | 5% |
Unspecified | 1 | 2% |
Biochemistry, Genetics and Molecular Biology | 1 | 2% |
Other | 0 | 0% |
Unknown | 9 | 21% |